Iceland· IS-EU/1/24/1884/001
Gohibic
A vilobelimab product containing vilobelimab, registered in Iceland by InflaRx GmbH. The same ATC class is registered in 8 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Vilobelimab is registered in 8 of 19 countries.
Countries holding a registration under ATC L04AJ10 (vilobelimab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 5 of them publish a price we can compare per daily dose
Vilobelimab · ATC L04AJ10
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Vilobelimab
- Manufacturer
- InflaRx GmbH
- Country
- Iceland (IS)
- ATC code
- L04AJ10
- ATC class
- Vilobelimab
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vilobelimab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGohibic 200 mgInflaRx
- CzechiaGOHIBICInflaRx GmbH, Jena
- FinlandGohibicInflaRx GmbH
- IrelandGohibic 200 mg Concentrate for solution for infusionInflaRx GmbH
- PolandGohibicInflaRx GmbH
- SwedenGohibic 200 mg Koncentrat till infusionsvätska, lösningInflaRx GmbH
- NetherlandsGohibic 200 mg concentraat voor oplossing voor infusieInflaRx GmbH
- United StatesGOHIBICInflaRx GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Gohibic
- Norway · Gohibic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2e3ef7f-44b5-433b-840a-cfc0403b3520 GET /v1/drugs/c2e3ef7f-44b5-433b-840a-cfc0403b3520?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AJ10",
"marketed": false,
"strength": "200 mg",
"ma_number": "EU/1/24/1884/001",
"substance": "Vilobelimab",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "45670"
}See everything about vilobelimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.